Will NICE’s New Medtech Evaluation Plans Hit the Target for Patients and Industry?

Concern That Rules-Based Pathway As Currently Proposed Is Too Limited To Secure Much-Needed Change

One year after the UK mooted the Rules-Based Pathway to give medtechs clarity on what can be expected from an evaluation, the devices industry says UK healthtech assessment and adoption processes are still failing to meet the needs of innovators and patients.

More from United Kingdom

More from Market Access